Day: March 29, 2024

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR Annual Meeting 2024 Phase 2 randomized trial in PDAC is underway with enrollment expected to complete in the fourth quarter of 2024 ELI-002 7P initial clinical trial data expected in the second quarter of 2024 Private placement with gross proceeds of $6.0 million closed in March 2024BOSTON, March 29, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights. “2023...

— Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 —— Exploring opportunities to expand KPI-012 into additional corneal indications —— Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 — ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. “In 2023, we focused on clinical execution, advancing...

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We have been focused on advancing our Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) cirrhosis program. We completed enrollment and randomization for the NAVIGATE Phase 2b/3 trial in 2023, and belapectin has consistently shown an encouraging safety profile, which was determined by our independent Data and Safety Monitoring Board on multiple reviews. We are pleased with the recent addition of Khurram Jamil, M.D., to our team. Dr. Jamil’s extensive experience...

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company HighlightsDurable single agent activity observed with MT-6402, a PD-L1 targeting direct-cell kill agent, in heavily pre-treated patients with low PD-L1+ head and neck cancer who had progressed on multiple prior therapies including checkpoint and EGFR antibodies. Enrollment is on-going in the dose escalation study with MT-8421, a novel CTLA-4 targeting agent...

Lectra: Availability of 2023 Annual Financial Report Paris, March 29, 2024 – Lectra announces that its 2023 Annual Financial Report has been released and filed with the French Financial Markets Authority (Autorité des marchés financiers). The 2023 Annual Financial Report containing the Management Report, the Report on Corporate Governance and Non-financial Statement is now available in the ESEF format (European Single Electronic Format) and in PDF version on the company’s website: https://www.lectra.com/fr/investisseurs. A condensed English version of the Annual Financial Report 2023 is also available on the company’s website: https://www.lectra.com/en/investors. About Lectra: As a major player in the fashion, automotive and furniture markets, Lectra contributes to the Industry 4.0 revolution with boldness and passion by providing...